Efficacy and safety of debranching technique with zone 1 thoracic endovascular aortic repair in high-risk patients with distal aortic arch lesions

分支血管重建术联合1区胸主动脉腔内修复术治疗远端主动脉弓病变高危患者的疗效和安全性

阅读:1

Abstract

BACKGROUND: To share the results of the debranching technique with zone 1 thoracic endovascular aortic repair (TEVAR) in high-risk patients chosen based on older age, cardiopulmonary comorbidities, and unfit for open surgical procedures, who have distal arch lesions. METHODS: Between January 2020 and August 2022, 15 patients treated in our practice were treated with the debranching technique TEVAR (d-TEVAR) for distal aortic arch lesions requiring a stent-graft landing in zone 1. We retrospectively reviewed clinical data and significant outcomes for prognostic analyses. Lesion types included chronic Stanford type B aortic dissections (n = 10), distal arch aneurysms (n = 4), and one pseudoaneurysm. All lesions were chronic, with no involvement of visceral vessels. These patients were considered high-risk in a multidisciplinary fashion. RESULTS: All procedures were completed with a technical success rate of 100%. The mean operative time was 317 ± 48 min. No in-hospital mortality or major complications were recorded. One patient had a type I endoleak at 3 months that was treated conservatively due to no symptoms during follow-up (median 16 months, (range 12-20)), and in one patient, this was associated with fatal cerebral infarction at 4 months following the procedure, yielding a stroke rate of 6.7%. Graft survival for all patients, via a Kaplan-Meier analysis, was 89.3%. CONCLUSIONS: For distal aortic arch lesions requiring a zone 1 stent-graft landing, d-TEVAR is an effective and safe alternative treatment option with promising short-term results in well-selected high-risk patients and can be applied when open surgery constitutes a significant surgical risk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。